- Publicerad
Redeye comments on Alligator Bioscience’s Q1 report, including the sub-optimal funding situation after the rights issue and upcoming catalysts, in particular the 18-month OPTIMIZE-1 readout.
Redeye
Redeye comments on Alligator Bioscience’s Q1 report, including the sub-optimal funding situation after the rights issue and upcoming catalysts, in particular the 18-month OPTIMIZE-1 readout.
Redeye